Grape Pomace for Blood Pressure: Plausible, Not Proven

A blood-pressure claim without the blood-pressure numbers

A branded grape pomace extract combined with L-arginine may lower blood pressure in people with grade 1–2 hypertension. The problem is that the published abstract of the only direct randomized controlled trial does not report the effect size in millimeters of mercury, the number of participants, the study duration, p-values, confidence intervals, or a description of the control treatment.

That leaves readers with a positive claim but no way to judge its clinical importance. A statistically significant change could be tiny; a larger change could be useful. Without the numbers, those are different possibilities, not conclusions.

The trial, reported by Abate et al. in 2026, tested Taurisolo®, a standardized grape pomace extract, plus L-arginine alongside standard antihypertensive therapy. The abstract reports sustained reductions in systolic and diastolic blood pressure, stable renal function, and improvements in several SF-12 quality-of-life domains: vitality, emotional well-being, and social functioning. Those results point in the expected direction. They do not establish how much the intervention helped, how long any benefit lasted, or whether a matched placebo controlled for expectations and behavior changes during the trial.

The biology behind the formulation makes sense. The clinical evidence does not yet justify treating it as a proven alternative to better-studied dietary approaches.

The pathway is real

Blood vessels relax when nitric oxide activates soluble guanylyl cyclase, which raises cyclic GMP in vascular smooth muscle. Less vascular resistance can mean lower blood pressure. Endothelial nitric oxide synthase makes nitric oxide using L-arginine as a substrate, so an arginine-plus-polyphenol product has an intuitive pitch: provide substrate for nitric oxide production and protect nitric oxide from oxidative damage.

Grape pomace contains polyphenols such as resveratrol, quercetin, catechins, and proanthocyanidins. These compounds can scavenge radicals, inhibit NADPH oxidase activity, and may increase endothelial nitric oxide synthase expression. In theory, reducing superoxide-mediated nitric oxide quenching could preserve more nitric oxide. That is a plausible mechanism, not proof that a grape extract lowers blood pressure in people.

A 2022 systematic review and meta-analysis of randomized trials placed grape-derived polyphenol foods among dietary interventions studied for vascular and endurance-related outcomes. It supports biological plausibility, but it does not provide blood-pressure-specific effect estimates for grape pomace. Exercise performance, endothelial biology, and clinical hypertension overlap; they are not interchangeable endpoints.

Beetroot sets a useful benchmark

The most informative dietary comparison comes from inorganic nitrate, not arginine. Nitrate follows a different route: the body converts it through the entero-salivary nitrate-to-nitrite pathway, which can generate nitric oxide independently of endothelial nitric oxide synthase.

In a 2022 systematic review and meta-analysis of beetroot juice trials, hypertensive patients had an average systolic blood-pressure reduction of 3.55 mmHg and a diastolic reduction of 1.32 mmHg. The interventions lasted 2 to 56 days. These are modest changes, but modest is not meaningless in blood pressure: the review notes epidemiologic estimates that a 2 mmHg reduction in systolic pressure corresponds to lower ischemic heart disease and stroke mortality at the population level.

That does not mean beetroot juice prevents those outcomes in every person, or that its trial results can be assigned to grape pomace. It does provide a practical standard. A new blood-pressure nutraceutical should disclose enough information to show whether its effect matches, exceeds, or falls short of a roughly 3.6 mmHg systolic reduction. The Taurisolo® abstract does not allow that comparison.

Why the L-arginine choice deserves scrutiny

The formulation's weakest link may be its nitric oxide precursor. Oral L-arginine sounds direct, but direct is not always efficient. Gut bacteria and systemic arginase enzymes extensively break down L-arginine, including conversion to ornithine, before it can support endothelial nitric oxide production.

The issue also goes beyond the amount of arginine circulating in blood. Endothelial nitric oxide synthase activity depends in part on the ratio of arginine to asymmetric dimethylarginine, or ADMA, a competitive inhibitor. Raising absolute arginine does not necessarily move that ratio enough to improve nitric oxide production.

A 2024 early-phase randomized trial of L-citrulline in pregnant people with chronic hypertension explains this pharmacokinetic problem directly: L-arginine undergoes extensive elimination by gut bacteria and systemic arginases, while the arginine:ADMA ratio helps govern endothelial nitric oxide synthase activity. The study concerns hypertension in pregnancy, so its clinical results should not be generalized wholesale to the grade 1–2 hypertension population in the Taurisolo® trial. Its explanation of arginine handling is still relevant to the formulation choice.

L-citrulline takes a different route. The kidneys convert it to L-arginine, allowing it to bypass much of the gut and hepatic arginase loss. In a 2022 randomized trial in hypertensive postmenopausal women, Maharaj et al. found that L-citrulline improved endothelial function. The authors describe arginase catabolism of L-arginine as a major contributor to reduced nitric oxide production in hypertensive women.

These findings do not prove that citrulline will lower blood pressure more than arginine in every setting, and they do not test Taurisolo®. They do make the use of oral L-arginine less compelling than the marketing logic suggests. The product may gain something from its polyphenol component, but the precursor component has known delivery limitations.

A randomized trial still needs transparent reporting

Randomization reduces confounding, but it does not rescue a report that withholds the details readers need to assess bias and precision. The Abate et al. abstract does not state whether the control group received a matched placebo or no additional treatment. That distinction matters. Without a matched placebo, participants and clinicians may change behavior because they know who received the intervention. Expectations, adherence to standard treatment, diet, activity, and measurement conditions can all influence an apparent blood-pressure effect.

The abstract also does not identify funding, manufacturer involvement, or author conflicts of interest, despite studying a registered trademark ingredient. A trademark does not establish bias. It does create a commercial stake that readers should be able to evaluate through clear disclosures. The abstract provides no such information.

Nor has independent human replication of grape pomace or Taurisolo® for blood pressure appeared in the evidence reviewed here. One positive trial can generate a hypothesis. Independent trials with transparent methods and complete effect estimates are what turn a hypothesis into a recommendation.

Mechanistic plausibility can justify a trial. It cannot substitute for a trial report that gives readers the result.

What to do with this evidence

If you have hypertension, do not treat a grape pomace and L-arginine supplement as a replacement for prescribed treatment. Blood pressure responds to medication, sodium intake, body weight, alcohol intake, physical activity, sleep, and underlying medical conditions; a supplement trial does not erase those realities.

For someone specifically interested in dietary nitric oxide pathways, nitrate-rich foods such as beetroot and leafy greens have the clearest independent blood-pressure evidence in this group of studies. Beetroot juice produced average reductions of 3.55 mmHg systolic and 1.32 mmHg diastolic in hypertensive patients across randomized trials, with intervention periods of up to 56 days.

Polyphenol-rich grape foods remain reasonable foods. Their broader health value does not depend on assigning a precise antihypertensive effect to one proprietary extract. If the goal is an oral amino-acid precursor for nitric oxide biology, the available mechanistic and clinical context favors L-citrulline over L-arginine, though that is not a prescription to self-treat hypertension.

Taurisolo® plus L-arginine is plausible, and its reported trial results deserve follow-up. Until the study provides participant numbers, duration, comparator details, effect sizes, uncertainty estimates, and conflict disclosures—and until independent groups replicate the finding—the responsible conclusion is narrower: the product has an unverified blood-pressure claim, while dietary nitrate has a quantified evidence base.